Literature DB >> 10388474

Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables.

A Virtanen1, M Gomari, R Kranse, U H Stenman.   

Abstract

BACKGROUND: Despite low specificity, serum prostate-specific antigen (PSA) is widely used in screening for prostate cancer. Specificity can be improved by measuring free and total PSA and by combining these results with clinical findings. Methods such as neural networks and logistic regression are alternatives to multistep algorithms for clinical use of the combined findings.
METHODS: We compared multilayer perceptron (MLP) and logistic regression (LR) analysis for predicting prostate cancer in a screening population of 974 men, ages 55-66 years. The study sample comprised men with PSA values >3 microg/L. Explanatory variables considered were age, free and total PSA and their ratio, digital rectal examination (DRE), transrectal ultrasonography, and a family history of prostate cancer.
RESULTS: When at least 90% sensitivity in the training sets was required, the mean sensitivity and specificity obtained were 87% and 41% with LR and 85% and 26% with MLP, respectively. The cancer specificity of an LR model comprising the proportion of free to total PSA, DRE, and heredity as explanatory variables was significantly better than that of total PSA and the proportion of free to total PSA (P <0.01, McNemar test). The proportion of free to total PSA, DRE, and heredity were used to prepare cancer probability curves.
CONCLUSION: The probability calculated by logistic regression provides better diagnostic accuracy for prostate cancer than the presently used multistep algorithms for estimation of the need to perform biopsy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388474

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Comparison of logistic regression and linear regression in modeling percentage data.

Authors:  L Zhao; Y Chen; D W Schaffner
Journal:  Appl Environ Microbiol       Date:  2001-05       Impact factor: 4.792

2.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

3.  The value of an artificial neural network in the decision-making for prostate biopsies.

Authors:  R P Meijer; E F A Gemen; I E W van Onna; J C van der Linden; H P Beerlage; G C M Kusters
Journal:  World J Urol       Date:  2009-06-28       Impact factor: 4.226

4.  [Parameters to improve the specificity of the prostate-specific antigen. Early detection of prostate cancer].

Authors:  C Börgermann; S Kliner; A Swoboda; H-J Luboldt; H Rübben
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

5.  [Significance of the PSA-concentration for the detection of prostate cancer].

Authors:  A Stachon
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

6.  Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.

Authors:  Carsten Stephan; Chuanliang Xu; Henning Cammann; Markus Graefen; Alexander Haese; Hartwig Huland; Axel Semjonow; Eleftherios P Diamandis; Mesut Remzi; Bob Djavan; Mark F Wildhagen; Bert G Blijenberg; Patrik Finne; Ulf-Hakan Stenman; Klaus Jung; Hellmuth-Alexander Meyer
Journal:  World J Urol       Date:  2007-02-28       Impact factor: 4.226

Review 7.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

8.  [An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l].

Authors:  C Stephan; B Vogel; H Cammann; M Lein; V Klevecka; P Sinha; G Kristiansen; D Schnorr; K Jung; S A Loening
Journal:  Urologe A       Date:  2003-03-22       Impact factor: 0.639

9.  LncRNA EGOT/miR-211-5p Affected Radiosensitivity of Rectal Cancer by Competitively Regulating ErbB4.

Authors:  Chunxiang Li; Hengchang Liu; Ran Wei; Zheng Liu; Haipeng Chen; Xu Guan; Zhixun Zhao; Xishan Wang; Zheng Jiang
Journal:  Onco Targets Ther       Date:  2021-04-28       Impact factor: 4.147

10.  Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity.

Authors:  Carsten Stephan; Nicola Büker; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung
Journal:  BMC Urol       Date:  2008-09-02       Impact factor: 2.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.